Bilal became interested in researching longevity and anti-aging supplements when his co-founder was researching nicotinamide mononucleotide (NMN), a nucleotide with anti-aging effects. Japan’s position as having the world’s most elderly population, its well-developed market of supplements for the elderly, and the ease to acquire talent from the numerous academic institutions already researching aging makes it the premier country for a longevity startup. Bilal was able to take advantage of the new startup visa scheme by Shibuya City to found ekei labs, which uses biomarkers to determine the presence and progression of various diseases associated with aging.

He explained why he started this event: “We want to help the community grow in Tokyo. Longevity is getting more and more traction, and it’s fantastic. We want to provide opportunities for like-minded people to connect and learn about exciting initiatives.”